

Conventional and microwave induced synthesis of various azetidinone and thiazolidinone derivatives from 3-[(1*E*)-1-aza-2-(2-chloro-7-methoxy-3-quinolyl)-vinyl]-4-(aryldiazenyl) phenol and their antimicrobial screening

Jigisha A Patel, B D Mistry * & K R Desai

Department of Chemistry, B. K. M. Science College, Valsad 396 001, Gujarat, India

E-mail I.D: bhavana.mistry@yahoo.com

Received 29 May 2007; accepted (revised) 7 April 2008

3-Chloro-4-(2-chloro-7-methoxy-3-quinolyl)-1-[3-hydroxy-6-(aryldiazenyl) phenyl] azetidin-2-one **2** and 2-(2-chloro-7-methoxy-3-quinolyl)-3-[3-hydroxy-6-(aryldiazenyl) phenyl]-1, 3-thiazolidin-4-one **3** have been synthesized by the reaction of 3-[(1*E*)-1-aza-2-(2-chloro-7-methoxy-3-quinolyl)-vinyl]-4-(aryldiazenyl) phenol **1** with chloroacetylchloride and mercapto acetic acid, respectively. Both the reactions have been carried out by conventional and microwave methods. These compounds have been screened for their antibacterial, antifungal and antitubercular activity against different microorganisms.

Keywords: Azetidinone, thiazolidinone, antibacterial, antifungal, antitubercular activity

Quinoline and their derivatives occur in numerous natural products. Many quinolines display interesting physiological activities¹ and have found important applications as pharmaceuticals^{2,3} (e.g., norfloxacin and ciprofloxacin). Moreover fused quinolines are known to bind DNA with high affinity, inhibit DNA topoisomerase and display cytotoxic and antitumour activities^{4,5}. For these reasons their synthesis has always attracted the attention of synthetic chemists. Many synthesis have been developed for quinolines^{6,7}, but due to their great importance, the development of novel synthetic methods remains an active research area⁸⁻¹⁰. Furthermore thiazolidinone derivatives found to possess a wide spectrum of biological activities¹¹⁻¹⁷.

Azetidin-2-one derivatives^{18,19} containing β -lactam nucleus has attracted considerable attention as they are endowed with a wide range of pharmaceutical activity^{20,21}. β -Lactam containing antibacterial agents has become an integral part of the chemotherapeutic arsenal available to today's medical practitioners. Although the number of existing agents are quite extensive, but the search for better and more effective drug is still going on.

The medicinal chemical approach to this search has throughout the years focused on synthetic route chemical reactions. It is well known that microwave irradiation technique is a powerful tool in organic synthesis^{22,23}.


Results and Discussion

The starting compounds 2-chloro-7-methoxy-3-formylquinoline^{24,25}, was condensed with 3-amino-4-(phenyldiazenyl) phenol under microwave irradiation in one pot to furnish the compound 3-[(1*E*)-1-aza-2-(2-chloro-7-methoxy-3-quinolyl)-vinyl]-4-(aryldiazenyl) phenol **1** in good yield.

Compound, 3-[(1*E*)-1-aza-2-(2-chloro-7-Methoxy-3-quinolyl-vinyl)-4-(aryldiazenyl) phenol **1** upon cyclization with chloroacetylchloride and 2-mercapto acetic acid by microwave irradiation technique yields the title compound **2a-s** and **3a-s**, respectively in good yield (**Scheme I**). The above mentioned compounds were also synthesized by the conventional method. It is noteworthy that the reaction which required 12-16 hr in conventional method in both steps, was completed within 5-7 min in Q-Pro-Modified Microwave system at 120 °C and power level of 500 W. Yield have been remarkably improved from 60 – 70 % to 80- 90 %.

Structure of compounds **1a-s**, **2a-s** and **3a-s** were established by their IR, ¹H NMR and mass spectral studies.

The yield and the physical constants of the compounds synthesized by the conventional and microwave irradiation methods are given (**Table I**).



Scheme I

Antitubercular activity

The *in vitro* tubercular evaluation of azetidinone and thiazolidinone derivatives (**2a-s** and **3a-s**) was studied against $H_{37}R_v$ strain of *Mycobacterium tuberculosis* using Lowenstein Jensen's egg medium by serial two fold dilution method and the retardation of growth rate studied up to six weeks at 37°C (Table II).

Antibacterial screening test

All the compounds **2a-s** and **3a-s** were subjected to *in vitro* screening against Gram-positive *Staphylococcus aureus* and Gram-negative *Eschericia coli* and *P.aeruginosa*. The minimum inhibitory concentration

(MIC) was determined using tube dilution method according to the standard procedure²⁶. Mueller Hinton broth was used as a culture medium. Sterilized medium was dispensed in each borosilicate glass test tube. The drug solution was added in order to attain final drug concentrations of 512, 256, 128, 64, 32, 16, 8, 4, 2, 1 $\mu\text{g/mL}$. Inoculums of standard suspension (0.1 mL of the test organism strain which contains 10^6 bacilli/mL) was added. The tubes were incubated at 37°C for 48 hr and then examined for the presence or absence of growth of the organism. The lowest concentration, which showed no visible growth, was taken as an end point minimum inhibitory concentration (MIC). The testing results are given in Table II.

Table I — Physical characterization data of compounds

| Compd | R | m.p. °C | Mol. Formula (Mol.wt) | Conventional | | Microwave | | (%) N . | |
|-------|--------------------|------------|---|--------------|--------------|---------------|--------------|---------|---------|
| | | | | Time (hr) | Yield (%) | Time (min) | Yield (%) | Found | (Calcd) |
| 2a | H | 201 | C ₂₅ H ₁₈ N ₄ O ₄ Cl ₂ | 12 | 74 | 5 | 88 | 11.40 | (11.36) |
| 2b | 2-OCH ₃ | 160 | C ₂₆ H ₂₀ N ₄ O ₄ Cl ₂ | 12 | 64 | 6 | 76 | 10.74 | (10.71) |
| 2c | 3-OCH ₃ | 120 | C ₂₆ H ₂₀ N ₄ O ₄ Cl ₂ | 12 | 67 | 6 | 80 | 10.75 | (10.71) |
| 2d | 4-OCH ₃ | 134 | C ₂₆ H ₂₀ N ₄ O ₄ Cl ₂ | 12 | 62 | 6 | 78 | 10.73 | (10.71) |
| 2e | 2-Br | 165 | C ₂₅ H ₁₇ N ₄ O ₃ BrCl ₂ | 12 | 58 | 5.5 | 72 | 9.84 | (9.79) |
| 2f | 3-Br | 156 | C ₂₅ H ₁₇ N ₄ O ₃ BrCl ₂ | 12 | 64 | 6 | 74 | 9.86 | (9.79) |
| 2g | 4-Br | 125 | C ₂₅ H ₁₇ N ₄ O ₃ BrCl ₂ | 12 | 69 | 5.5 | 83 | 9.87 | (9.79) |
| 2h | 2-Cl | 176 | C ₂₅ H ₁₇ N ₄ O ₃ Cl ₃ | 12 | 71 | 5 | 81 | 10.66 | (10.62) |
| 2i | 3-Cl | 185 | C ₂₅ H ₁₇ N ₄ O ₃ Cl ₃ | 12 | 69 | 5 | 78 | 10.65 | (10.62) |
| 2j | 4-Cl | 162 | C ₂₅ H ₁₇ N ₄ O ₃ Cl ₃ | 12 | 75 | 5 | 78 | 10.63 | (10.62) |
| 2k | 2-NO ₂ | 171 | C ₂₅ H ₁₇ N ₅ O ₅ Cl ₂ | 12 | 55 | 5.5 | 83 | 13.05 | (13.01) |
| 2l | 3-NO ₂ | 140 | C ₂₅ H ₁₇ N ₅ O ₅ Cl ₂ | 12 | 62 | 6 | 67 | 13.03 | (13.01) |
| 2m | 4-NO ₂ | 153 | C ₂₅ H ₁₇ N ₅ O ₅ Cl ₂ | 12 | 69 | 6 | 72 | 13.04 | (13.01) |
| 2n | 2-CH ₃ | 152 | C ₂₆ H ₂₀ N ₄ O ₃ Cl ₂ | 12 | 73 | 5 | 79 | 11.05 | (11.04) |
| 2o | 3-CH ₃ | 167 | C ₂₆ H ₂₀ N ₄ O ₃ Cl ₂ | 12 | 70 | 5 | 88 | 11.08 | (11.04) |
| 2p | 4-CH ₃ | 173 | C ₂₆ H ₂₀ N ₄ O ₃ Cl ₂ | 12 | 66 | 5 | 81 | 11.07 | (11.04) |
| 2q | 2-F | 185 | C ₂₅ H ₁₇ N ₄ O ₃ FCI ₂ | 12 | 54 | 6 | 76 | 10.97 | (10.96) |
| 2r | 3-F | 158 | C ₂₅ H ₁₇ N ₄ O ₃ FCI ₂ | 12 | 57 | 5.5 | 65 | 10.99 | (10.96) |
| 2s | 4-F | 148 | C ₂₅ H ₁₇ N ₄ O ₃ FCI ₂ | 12 | 59 | 6 | 68 | 10.98 | (10.96) |
| 3a | H | >300 | C ₂₅ H ₁₉ N ₄ O ₃ SCl | 16 | 69 | 6 | 78 | 11.45 | (11.41) |
| 3b | 2-OCH ₃ | 255 | C ₂₆ H ₂₁ N ₄ O ₄ SCl | 16 | 71 | 6 | 86 | 10.79 | (10.75) |
| 3c | 3-OCH ₃ | 222 | C ₂₆ H ₂₁ N ₄ O ₄ SCl | 16 | 69 | 6 | 80 | 10.80 | (10.75) |
| 3d | 4-OCH ₃ | 184 | C ₂₆ H ₂₁ N ₄ O ₄ SCl | 16 | 74 | 6.5 | 81 | 10.76 | (10.75) |
| 3e | 2-Br | >300 | C ₂₅ H ₁₈ N ₄ O ₃ SBrCl | 16 | 76 | 7 | 83 | 9.88 | (9.83) |
| 3f | 3-Br | 210 | C ₂₅ H ₁₈ N ₄ O ₃ SBrCl | 16 | 66 | 6.5 | 79 | 9.85 | (9.83) |
| 3g | 4-Br | 236 | C ₂₅ H ₁₈ N ₄ O ₃ SBrCl | 16 | 76 | 7 | 89 | 9.84 | (9.83) |
| 3h | 2-Cl | >300 | C ₂₅ H ₁₈ N ₄ O ₃ SCl ₂ | 16 | 68 | 6.5 | 80 | 10.71 | (10.66) |
| 3i | 3-Cl | 165 | C ₂₅ H ₁₈ N ₄ O ₃ SCl ₂ | 16 | 73 | 7 | 88 | 10.68 | (10.66) |
| 3j | 4-Cl | 150 | C ₂₅ H ₁₈ N ₄ O ₃ SCl ₂ | 16 | 68 | 6 | 78 | 10.67 | (10.66) |
| 3k | 2-NO ₂ | 187 | C ₂₅ H ₁₈ N ₅ O ₅ SCl | 16 | 62 | 6 | 76 | 13.11 | (13.07) |
| 3l | 3-NO ₂ | 142 | C ₂₅ H ₁₈ N ₅ O ₅ SCl | 16 | 66 | 6 | 83 | 13.10 | (13.07) |
| 3m | 4-NO ₂ | 148 | C ₂₅ H ₁₈ N ₅ O ₅ SCl | 16 | 59 | 6.5 | 75 | 13.9 | (13.07) |
| 3n | 2-CH ₃ | 136 | C ₂₆ H ₂₁ N ₄ O ₄ SCl | 16 | 78 | 6.5 | 85 | 11.13 | (11.09) |
| 3o | 3-CH ₃ | 115 | C ₂₆ H ₂₁ N ₄ O ₃ SCl | 16 | 73 | 6.5 | 87 | 11.14 | (11.09) |
| 3p | 4-CH ₃ | 125 | C ₂₆ H ₂₁ N ₄ O ₃ SCl | 16 | 68 | 6.5 | 79 | 11.17 | (11.09) |
| 3q | 2-F | 138 | C ₂₅ H ₁₈ N ₄ O ₃ SFCI | 16 | 63 | 7 | 74 | 11.05 | (11.01) |
| 3r | 3-F | 188 | C ₂₅ H ₁₈ N ₄ O ₃ SFCI | 16 | 69 | 7 | 85 | 11.06 | (11.01) |
| 3s | 4-F | 130 | C ₂₅ H ₁₈ N ₄ O ₃ SFCI | 16 | 60 | 7 | 77 | 11.04 | (11.01) |

Antifungal activity

The antifungal activity of compounds **2a-s** and **3a-s** has been assayed *in vitro* at a concentration of 256 µg/mL and 512 µg/mL against *Candida albicans*, which were maintained on nutrient agar slants, which

were stored at 4°C. None of the compounds was found to possess better activity than Dithane-M 45 (**Table II**).

All the compounds were tested for their effect on the growth of microbial cultures at concentration level

Table II — Antimicrobial activity of compounds **2a-s** and **3a-s**

| Table II — Antimicrobial activity of compounds 2a-s and 3a-s | | | | | | | | | |
|--|------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|--|
| Compd | Antimicrobial Activity | | | | | | | | Antitubercular Activity $\mu\text{g/mL}$ H ₃₇ Ra strain of M. tuberculosis |
| | <i>E.coli</i> | | <i>P.aeruginosa</i> | | <i>S. aureus</i> | | <i>C. albicans</i> | | |
| | 256 $\mu\text{g/mL}$ | 512 $\mu\text{g/mL}$ | 256 $\mu\text{g/mL}$ | 512 $\mu\text{g/mL}$ | 256 $\mu\text{g/mL}$ | 512 $\mu\text{g/mL}$ | 256 $\mu\text{g/mL}$ | 512 $\mu\text{g/mL}$ | |
| 2a | - | ++ | + | ++ | - | ++ | + | ++ | >600 |
| 2b | + | ++ | ++ | ++ | + | ++ | + | ++ | >600 |
| 2c | + | ++ | ++ | ++ | + | ++ | + | ++ | >600 |
| 2d | + | ++ | ++ | ++ | ++ | +++ | + | ++ | >600 |
| 2e | ++ | +++ | + | ++ | ++ | +++ | + | ++ | >600 |
| 2f | ++ | +++ | + | ++ | ++ | +++ | + | ++ | >600 |
| 2g | ++ | +++ | + | ++ | ++ | +++ | ++ | ++ | >600 |
| 2h | ++ | +++ | ++ | +++ | ++ | +++ | ++ | ++ | >600 |
| 2i | ++ | +++ | ++ | +++ | ++ | ++ | ++ | ++ | >600 |
| 2j | ++ | +++ | ++ | +++ | ++ | ++ | - | + | >600 |
| 2k | + | ++ | + | ++ | ++ | ++ | - | + | >600 |
| 2l | + | ++ | + | ++ | + | + | - | + | >600 |
| 2m | + | ++ | + | ++ | ++ | + | - | + | >600 |
| 2n | + | ++ | + | ++ | + | + | + | + | >600 |
| 2o | + | ++ | + | ++ | - | + | - | - | >600 |
| 2p | + | ++ | + | ++ | + | + | + | + | >600 |
| 2q | +++ | +++ | +++ | +++ | ++ | +++ | + | ++ | >600 |
| 2r | +++ | +++ | +++ | +++ | ++ | +++ | + | ++ | >600 |
| 2s | +++ | +++ | +++ | +++ | ++ | +++ | + | ++ | >600 |
| 3a | - | + | + | ++ | - | ++ | + | ++ | >600 |
| 3b | + | + | ++ | ++ | + | ++ | + | ++ | >600 |
| 3c | + | + | ++ | ++ | + | ++ | + | ++ | >600 |
| 3d | + | ++ | ++ | ++ | ++ | +++ | + | ++ | >600 |
| 3e | + | +++ | + | ++ | ++ | +++ | + | ++ | >600 |
| 3f | + | +++ | + | ++ | ++ | +++ | + | ++ | >600 |
| 3g | + | +++ | + | ++ | ++ | +++ | ++ | ++ | >600 |
| 3h | + | +++ | ++ | +++ | ++ | +++ | ++ | ++ | >600 |
| 3i | + | +++ | ++ | +++ | ++ | ++ | ++ | ++ | >600 |
| 3j | + | +++ | ++ | +++ | ++ | ++ | - | + | >600 |
| 3k | - | ++ | + | ++ | ++ | ++ | - | + | >600 |
| 3l | - | ++ | + | ++ | + | + | - | + | >600 |
| 3m | - | ++ | + | ++ | ++ | + | - | + | >600 |
| 3n | - | ++ | + | ++ | + | + | + | + | >600 |
| 3o | - | ++ | + | ++ | - | - | - | - | >600 |
| 3p | - | ++ | + | ++ | + | + | + | + | >600 |
| 3q | + | +++ | +++ | +++ | ++ | +++ | + | ++ | >600 |
| 3r | + | +++ | +++ | +++ | ++ | +++ | + | ++ | >600 |
| 3s | + | +++ | +++ | +++ | ++ | +++ | + | ++ | >600 |
| Streptomycin | ++++ | ++++ | ++++ | ++++ | ++++ | ++++ | - | - | - |
| Dithane-M 45 | - | - | - | - | - | - | ++++ | ++++ | - |
| INH | - | - | - | - | - | - | - | - | 0.05 |

(-)< 6mm, (+)=7 – 10 mm, (++)=11 – 15mm,(+++)= 16 – 21mm,(++++)= 22 – 28mm

(-)< 6mm, (+)=7 – 10 mm, (++)=11 – 15mm,(+++)= 16 – 21mm,(++++)= 22 – 28mm

ranging from 128-512 µg/mL on different organisms. Compounds **2q**, **2r**, **2s**, **3q**, **3r** and **3s** showed lower MIC values against both gram positive and gram negative bacteria strains. The MIC level of azetidinone **2a-s** and thiazolidinone **3a-s** against these organisms are given in **Table II**.

The presence of fluoro, bromo or chloro group in the moiety enhances its antimicrobial activity. However, the degree of inhibition varied both with the test compound as well as with the bacterial species. Compounds **2q**, **2r** and **2s** show significant activity at 256µg/mL concentration against *E.coli*, *P.aeruginosa*, and *S.aureus*.

An examination of the data reveals that almost all the compound showed good to moderate antimicrobial activity.

Experimental Section

All the melting points were taken in open capillary tube and are uncorrected. The IR spectra were recorded with KBr on Shimadzu FT-IR 8300 spectrophotometer. Purity of the compounds in addition to elemental analysis was checked by Thin Layer Chromatography using silica gel-G coated Al plates (Merck) and spots were visualized by exposing the dry plates in iodine vapors, using benzene:ethyl acetate:ethanol (6:2:2). ¹H NMR spectra were recorded in CDCl₃ on a Bruker DRX-300 at 200MHz using TMS as an internal standard and mass spectra on a JEOL SX 102/DA-6000 Mass spectrometer/Data system using Argon/Xenon(6kV,10 mA) as the FAB gas.

General procedure for the synthesis of substituted 3-[(1E)-1-aza-2-(2-chloro-7-methoxy-3-quinolyl)-vinyl]-4-(aryldiazenyl) phenol (1a-s)

A mixture of 2-chloro-7-methoxy-3-formyl-quinoline (0.01mole), 3- amino -4-(aryldiazenyl) phenol (0.01 mole) and glacial acetic acid (2 mL) was dissolved in ethanol. Then the well stirred mixture was refluxed for 6-7 hr (In Q Pro-M modified microwave system; at 90°C temp. and 500 W Power level, reaction was completed in 2-3 min.).The reaction-mixture was then cooled, concentrated and poured into crushed ice. The product obtained was filtered, washed with water and recrystallized from ethanol.

3-[(1E)-1-Aza-2-(2-chloro-7-methoxy-3-quinol-yl)-vinyl]-4-(phenyldiazenyl) phenol 1 (1a): ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.75 (dd, 1H, *J*_{6,8} =

2.20 & *J*_{6,5} = 8.75 Hz, C₆-H), 7.39 (s, 1H, C₈-H), 7.15 (d, 1H, *J*_{5,6} = 8.75 Hz, C₅-H), 8.56 (s, 1H, C₄-H), 9.755 (s, 1H, -CH=N), 7.02 (d, 1H, *J*_{4,2} = 2.50 & *J*_{4,5} = 8.17 Hz, C₄-H), 7.06 (s, 1H, *J*_{2,4} = 2.50 Hz, C₂-H), 7.392 (d, 1H, *J*_{5,4}=8.17 Hz, C₅-H), 7.40-8.70 (m, 5H, Ar-H), 3.84 (s, 3H, -O-CH₃), 10.25 (s, 1H, Ar-OH); IR(KBr): 3446 (-OH), 1576 (CH=N), 1570 (C=N), 1417 (N=N) cm⁻¹, MS, *m/z*: 417, 219, 198, 193, 157, 142, 133, 121, 114, 93.

General procedure for the synthesis of substituted 3-chloro-4-(2-chloro-7-methoxy-3-quinolyl)-1-[3-hydroxy-6-(aryldiazenyl) phenyl] azetidin-2-one 2a-s

A mixture of 3-[(1E)-1-aza-2-(2-chloro-7-methoxy-3-quinolyl)-vinyl]-4-(aryldiazenyl) phenol **1** (0.01 mole) and triethylamine (0.02 mole) was dissolved in 1,4-dioxane (50 mL). To this well stirred cooled solution chloroacetylchloride (0.02 mole) was added drop wise during 20 min. The reaction-mixture was then stirred for further 1hr and refluxing for 12 hr (in Q Pro-M modified microwave system; reaction was completed in 4-5 min at power level 500 W) at 120°C. The triethylamine hydrochloride salt formed was filtered to separate the salt. The filtrate was concentrated to half of its initial volume and then poured onto crushed ice. The product obtained was filtered, washed with water and recrystallized from ethanol.

3-Chloro-4-(2-chloro-7-methoxy-3-quinolyl)-1-{3-hydroxy-6-[(3-methoxyphenyl) diazenyl]phenyl} azetidin-2-one 2c: ¹H NMR (300 MHz, DMSO-*d*₆): δ 6.95 (dd, 1H, *J*_{6,8} = 2.15 & *J*_{6,5}=8.79 Hz, C₆-H), 7.02 (s, 1H, C₈-H), 7.77 (d, 1H, *J*_{5,6} = 8.79 Hz, C₅-H), 8.37 (s, 1H, C₄-H), 5.20 (s, ¹H, CH-N β-lactam), 5.32 (s, 1H, CH-C β-lactam), 7.05 (d, 1H, *J*_{4,2} = 1.7 & *J*_{4,5}=8.17 Hz, C₄-H), 7.36 (d, 1H, *J*_{5,4} = 8.17Hz, C₅-H), 7.80-8.70 (m, 5H, Ar-H), 3.78 (s, 3H, -O-CH₃), 3.85(s, 3H, -O-CH₃), 10.0 (s, 1H, Ar-OH);IR (KBr) : 3503 (-OH, str, phenolic), 1734 (C=O β-Lactam), 1536 (C-N), 1419 (N=N) cm⁻¹, MS, *m/z*: 523(M⁺), 527(M⁺+4), 267, 232, 228, 219, 213, 198, 194, 185, 121.

General procedure for the synthesis of substituted 2-(2-chloro-7-methoxy-3-quinolyl)-3-[3-hydroxy-6-(aryldiazenyl) phenyl]-1, 3-thiazolidin-4-one 3a-s

A mixture of 3-[(1E)-1-aza-2-(2-chloro-7-methoxy-3-quinolyl)-vinyl]-4-(aryldiazenyl) phenol **1** (0.01 mole) and catalytic amount of aluminium chloride

(0.05 g) in benzene was taken in Dean stark apparatus and to it thioglycolic acid (1.40 mL, 0.02 mole) in DMF was added slowly. The reaction mass was refluxed for 16 hr (Q Pro-M modified microwave system. The reaction- mixture was refluxed for 6-7 min at Power level 450 W) at 120-125°C constant temperature. The benzene was distilled off to get the solid mixture. This was then triturated with an excess of 10% sodium bicarbonate solution to remove excess of mercapto acetic acid. The product obtained was filtered, washed several times with water and recrystallized from ethanol.

2-(2-Chloro-7-methoxy(3-quinolyl)-3-{3-hydroxy-6-[(3-methoxyphenyl)diazenyl] phenyl}-1, 3-thiazolidin-4-one 3c: ^1H NMR (300 MHz, DMSO- d_6): δ 6.744 (dd, 1H, $J_{6-8} = 2.20$ and $J_{6-5} = 8.43$ Hz, C₆-H), 6.98 (s, 1H, C₈-H), 7.90 (d, 1H, $J_{5-6} = 8.43$ Hz, C₅-H), 8.29 (s, 1H, C₄-H), 4.40 (s, 2H, S-CH₂), 6.36 (s, 1H, -CH-N), 7.10 (d, 1H, $J_{4-2} = 1.80$ and $J_{4-5} = 8.06$ Hz, C₄-H), 7.07 (d, 1H, $J_{2-4} = 2.50$ Hz, C₂-H), 7.368 (d, 1H, $J_{5-4} = 8.17$ Hz, C₅-H), 7.44-7.60 (m, 5H, Ar-H), 3.76 (s, 3H, -O-CH₃), 3.86 (s, 3H, -O-CH₃), 10.0 (s, Ar-OH); IR (KBr): 3421 (-OH), 1738 (C=O, thiazolidinone), 1559.8 (C=N), 1535 (C-N), 1417 (N=N), 616 (C-S-C) cm^{-1} , MS, m/z : 521(M^+), 523($\text{M}^+ + 2$), 295, 248, 228, 213, 198, 185, 121.

Acknowledgement

The authors are grateful to the Department of Chemistry, B. K. M. Science College Valsad (Veer Narmad South Gujarat University, Surat) for providing research facilities and CDRI, Lucknow and IIT, Mumbai for providing mass spectra and NMR spectra respectively.

References

- Landquist J K in *Comprehensive Heterocyclic Chemistry*, edited by Katritzky A R, Rees C W & Scrivan E F V (Pergamon Press, Oxford), 2(1.06), **1984**, 146.
- Yoshikazu A, Kazuhiko I, Fujio I, Masaki H & Takayoshi I, *J Med chem*, 48, **2005**, 3194.
- Thiruvarama S R, Sampathkumar N & Rajendram S P, *Indian J Chem*, 44B, **2002**, 2608.
- Spicer J A, Gamage S A, Atwell G J, Finlay G J, Bangulay B C & Denny W A, *J Med chem*, 40, **1997**, 1919.
- Lyon M A, Lawrence S, William D J & Jackson Y A, *J Chem Soc Perkin Trans*, 1, **1999**, 437.
- Judit T, Gabor B, Andrasan D, Laszlo T & Miklos N, *Synthetic Communications*, 36, **2006**, 3581.
- Katritzky A R & Michael A, *J Org chem*, 63, **1998**, 9989.
- Shaabani A, Soleimani Ebrahim & Badri Z, *Synthetic Communications*, 37, **2007**, 629.
- Halehatty S, Bhojya N, Machenahalli S R, Boovanahalli V S & Thopenahalli R R, *Phosphorus, Sulfur, and Silicon*, 181, **2006**, 541.
- Belalakatte P N, Doyijode B, Kumar A & Kittappa M M, *Phosphorus, Sulfur, and Silicon*, 181, **2006**, 2003.
- Patel K D, Mistry B D & Desai K R, *J Indian Chem Soc*, 81, **2004**, 783.
- Yadav R, Srivastava S D & Srivastava S K, *Indian J Chem*, 44B, **2005**, 1262.
- El-Desoky S I, Bondock S B, Etman H A, Fadda A A & Metwally M D, *Sulfur Letters*, 26, **2003**, 127.
- Selvi G & Rajendran S P, *Asian J Chem*, 16, **2004**, 1017.
- Datta N J, Khunt R C & Parikh A R, *Ind J Chem*, 41B, **2002**, 433.
- Kansagra B P, Bhatt H H & Parikh A R, *Indian J Heterocycl Chem*, 10, **2000**, 5.
- Dobaria A V, Patel J R, Padaliya J V & Parekh H H, *Indian J Heterocycl Chem*, 11, **2001**, 115.
- Desai K G & Desai K R, *Indian J Chem*, 44B, **2005**, 2093.
- Pandey V K, Gupta V D, Upadhyay M, Upadhyay M, Singh V K & Tanden M, *Indian J Chem*, 44B, **2005**, 158.
- Rosenblun S B, Huynh T, Adriano, Afonso, Davis H R, Cladler J W & Burnedt D A, *J Med Chem*, 41, **1998**, 973.
- Thaker K M, Kachhadia V V & Joshi H S, *Indian J Chem*, 42B, **2003**, 1544.
- El-Sayed H, El-Ashry A, El-Sayed R, Hmida A H, & Hagar M, *Synthetic Communications*, 35, **2005**, 2243.
- Desai K G & Desai K R, *Indian J Chem*, 44B, **2005**, 2097.
- Srivastava A & Singh R M, *Indian J Chem*, 44B, **2005**, 1868.
- Bhat B & Bhaduri A P, *Indian J Chem*, 23B, **1984**, 33.
- Andrews J M, *J Antimicrobial Chemotherapy*, 48, **2001**, 5.